These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28596225)

  • 1. Increased warfarin requirements in a patient with chronic hepatitis C infection receiving sofosbuvir and ribavirin.
    Peterson D; Van Ermen A
    Am J Health Syst Pharm; 2017 Jun; 74(12):888-892. PubMed ID: 28596225
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Influence of Successful Chronic Hepatitis C Virus Treatment with Ledipasvir/Sofosbuvir on Warfarin Dosing Requirements in Four Veterans.
    Britnell SR; Willets AE; Vanderman AJ; Woodard CL; Britt RB
    Pharmacotherapy; 2016 Nov; 36(11):1173-1179. PubMed ID: 27716978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Reduction in warfarin effect associated with sofosbuvir-velpatasvir.
    Rindone JP; Mellen CK
    Am J Health Syst Pharm; 2017 Sep; 74(17):1308-1311. PubMed ID: 28842460
    [No Abstract]   [Full Text] [Related]  

  • 4. Patient-reported outcomes with sofosbuvir and velpatasvir with or without ribavirin for hepatitis C virus-related decompensated cirrhosis: an exploratory analysis from the randomised, open-label ASTRAL-4 phase 3 trial.
    Younossi ZM; Stepanova M; Charlton M; Curry MP; O'Leary JG; Brown RS; Hunt S
    Lancet Gastroenterol Hepatol; 2016 Oct; 1(2):122-132. PubMed ID: 28404069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apparent interaction between telaprevir and warfarin in a patient with chronic hepatitis C viral infection.
    Gatti DC; Cha A
    Am J Health Syst Pharm; 2012 Dec; 69(23):2062-5. PubMed ID: 23172264
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sofosbuvir plus ribavirin in treatment-naïve patients with chronic hepatitis C virus genotype 1 or 3 infection in India.
    Shah SR; Chowdhury A; Mehta R; Kapoor D; Duseja A; Koshy A; Shukla A; Sood A; Madan K; Sud R; Nijhawan S; Pawan R; Prasad M; Kersey K; Jiang D; Svarovskaia E; Doehle B; Kanwar B; Subramanian M; Acharya SK; Sarin S
    J Viral Hepat; 2017 May; 24(5):371-379. PubMed ID: 27933698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sofosbuvir and ribavirin for 6 weeks is not effective among people with recent hepatitis C virus infection: The DARE-C II study.
    Martinello M; Gane E; Hellard M; Sasadeusz J; Shaw D; Petoumenos K; Applegate T; Grebely J; Maire L; Marks P; Dore GJ; Matthews GV
    Hepatology; 2016 Dec; 64(6):1911-1921. PubMed ID: 27639183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4.
    Doss W; Shiha G; Hassany M; Soliman R; Fouad R; Khairy M; Samir W; Hammad R; Kersey K; Jiang D; Doehle B; Knox SJ; Massetto B; McHutchison JG; Esmat G
    J Hepatol; 2015 Sep; 63(3):581-5. PubMed ID: 25937436
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a Potential Interaction Between New Regimens to Treat Hepatitis C and Warfarin.
    DeCarolis DD; Westanmo AD; Chen YC; Boese AL; Walquist MA; Rector TS
    Ann Pharmacother; 2016 Nov; 50(11):909-917. PubMed ID: 27465881
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial.
    Kowdley KV; Lawitz E; Crespo I; Hassanein T; Davis MN; DeMicco M; Bernstein DE; Afdhal N; Vierling JM; Gordon SC; Anderson JK; Hyland RH; Dvory-Sobol H; An D; Hindes RG; Albanis E; Symonds WT; Berrey MM; Nelson DR; Jacobson IM
    Lancet; 2013 Jun; 381(9883):2100-7. PubMed ID: 23499440
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
    Lawitz E; Lalezari JP; Hassanein T; Kowdley KV; Poordad FF; Sheikh AM; Afdhal NH; Bernstein DE; Dejesus E; Freilich B; Nelson DR; Dieterich DT; Jacobson IM; Jensen D; Abrams GA; Darling JM; Rodriguez-Torres M; Reddy KR; Sulkowski MS; Bzowej NH; Hyland RH; Mo H; Lin M; Mader M; Hindes R; Albanis E; Symonds WT; Berrey MM; Muir A
    Lancet Infect Dis; 2013 May; 13(5):401-8. PubMed ID: 23499158
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful sofosbuvir treatment with ribavirin dose reduction for chronic hepatitis C virus genotype 2 infection in a patient with ulcerative colitis: a case report.
    Ohta Y; Kanda T; Katsuno T; Yasui S; Haga Y; Sasaki R; Nakamura M; Wu S; Nakamoto S; Arai M; Yokosuka O
    BMC Gastroenterol; 2016 Jul; 16(1):66. PubMed ID: 27401874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
    Tong MJ; Chang PW; Huynh TT; Rosinski AA; Tong LT
    J Dig Dis; 2016 Feb; 17(2):113-21. PubMed ID: 26749171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection.
    Gane EJ; Hyland RH; An D; Svarovskaia E; Pang PS; Brainard D; Stedman CA
    Gastroenterology; 2015 Nov; 149(6):1454-1461.e1. PubMed ID: 26261007
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of sofosbuvir plus ribavirin in treatment-naive patients with genotype-1 and -3 HCV infection: results from a Russian Phase IIIb study.
    Isakov V; Zhdanov K; Kersey K; Svarovskaia E; Massetto B; Zhu Y; Knox SJ; Bakulin I; Chulanov V
    Antivir Ther; 2016; 21(8):671-678. PubMed ID: 27376706
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new regimen for starting warfarin therapy in out-patients.
    Oates A; Jackson PR; Austin CA; Channer KS
    Br J Clin Pharmacol; 1998 Aug; 46(2):157-61. PubMed ID: 9723825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence.
    Poordad F; Schiff ER; Vierling JM; Landis C; Fontana RJ; Yang R; McPhee F; Hughes EA; Noviello S; Swenson ES
    Hepatology; 2016 May; 63(5):1493-505. PubMed ID: 26754432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A potential interaction between warfarin and atovaquone.
    Hidalgo K; Lyles A; Dean SR
    Ann Pharmacother; 2011 Jan; 45(1):e3. PubMed ID: 21189363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
    Tacke F; Günther R; Buggisch P; Klinker H; Schober A; John C; Lutz T; Pfeiffer-Vornkahl H; Niederau C; Cornberg M; Sarrazin C; Mauss S
    Liver Int; 2017 Feb; 37(2):205-211. PubMed ID: 27428297
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.